S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.53
+1.85
+11.09%
AEMD · Aethlon Medical, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Aethlon Medical Inc (AEMD)
NASDAQ NMS - GLOBAL MARKET
Health Care
$5.10
-0.26
(-4.85%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$5.10
$5.10
$5.10
52-WEEK RANGE
$5.10
$1.41
$29.45
What's happening
- AEMD is down 4.85% today, trading at $5.10. — Live quote
- Volume today (110) is well below its 3-month average of 1,836,680. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-4.02 actual vs. $-0.80 estimated (-402.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 4
Sell 1
Strong sell 2
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AEMD
-62.74%
vs S&P 500
-75.14%
1-YEAR RETURN
AEMD
-80.99%
vs S&P 500
-96.36%
6-MONTH RETURN
AEMD
-55.52%
3-MONTH RETURN
AEMD
+71.43%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q1 2027)
$-4.02
Est. $-0.80
MISS -402.1%
2026-04-26 (Q4 2026)
$-1.49
Est. $-2.06
BEAT +27.3%
2026-01-26 (Q3 2026)
$-2.45
Est. $-2.47
BEAT +0.7%
2025-10-26 (Q2 2026)
$-3.74
Est. $-3.74
MISS -0.1%
Valuation Measures & Ratios
Enterprise Value4$3.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)15.39
Price / Book70.38
EV4 / Revenue6.74
EV4 / EBITDA—
Profit Margin-433.33%
Operating Margin-435.09%
Return on Equity (ROE8)-123.09%
Return on Assets (ROA9)-99.29%
Avg Volume (3M)1,836,680
Quarterly history (5 periods)
| Measure | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 |
|---|---|---|---|---|---|
| Market cap | $1.6M | $10.5M | $14.8M | $2.6M | $60.7M |
| P/E | -0.23 | -1.50 | -1.90 | -0.29 | -5.73 |
| Price/Book | 0.31 | 1.57 | 2.58 | 0.75 | 14.01 |
| EV/EBITDA | 0.50 | -0.52 | -1.17 | — | — |
| ROE | -131.08% | -104.60% | -135.93% | -259.82% | -244.55% |
| ROA | -109.30% | -87.15% | -106.66% | -167.64% | -162.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short75,446
Change from Prior Settlement+0.80%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -433.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -81.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AEMD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$1.6M | -$2.1M | -$1.5M | -$1.8M | -$1.8M | -$2.9M | -$2.6M | -$3.6M |
| Net income | -$1.5M | -$2.0M | -$1.5M | -$1.8M | -$1.8M | -$2.8M | -$2.6M | -$3.5M |
| EPS (diluted) | $-4.02 | $-2.45 | $-3.74 | $-42.42 | $-10.05 | $-16.11 | $-2.76 | $-1.37 |
| EPS (basic) | $-4.02 | $-2.45 | $-3.74 | $-42.42 | $-10.05 | $-16.11 | $-2.76 | $-1.37 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $6.2M | $6.3M | $8.1M | $7.3M | $5.3M | $7.4M | $6.5M | $8.8M |
| Total liabilities | — | $1.4M | $1.3M | $1.6M | $1.9M | $2.2M | $2.2M | $2.8M |
| Stockholders' equity | $5.2M | $4.9M | $6.7M | $5.7M | $3.4M | $5.1M | $4.3M | $6.0M |
| Total current assets | $5.6M | $5.6M | $7.1M | $6.3M | $4.1M | $5.9M | $5.0M | $7.1M |
| Total current liabilities | $1.0M | $1.4M | $1.3M | $1.4M | $1.6M | $1.9M | $1.8M | $2.3M |
| Cash & equivalents | $4.9M | $5.0M | $7.0M | $5.9M | $3.8M | $5.5M | $4.8M | $6.9M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $293.1K | $356.8K | $434.2K | $514.0K | $593.7K | $676.2K | $762.1K | $843.6K |
| Intangible assets | — | $0 | $138 | $275 | $413 | $550 | $688 | $825 |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $411.4K | $384.6K | $469.5K | $570.8K | $571.5K | $534.5K | $610.9K | $922.9K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $301.4K | $657.3K | $219.2K | $261.1K | $364.5K | $472.2K | — | — |
| Common stock & paid-in capital | $477 | $314 | $973 | $761 | $2.6K | $259 | $14.0K | $14.0K |
| Retained earnings | -$176.7M | -$175.1M | -$173.2M | -$171.2M | -$169.7M | -$168.0M | -$161.7M | -$159.9M |
| Accumulated other comprehensive income (loss) | -$38.9K | -$32.7K | -$29.8K | -$26.4K | -$22.4K | -$17.1K | -$17.0K | -$4.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$1.8M | -$1.9M | -$1.7M | -$1.7M | -$1.7M | -$2.0M | -$2.2M |
| Investing cash flow | -$9.2K | -$2.1K | -$1.7K | — | $0 | $2.2K | -$2.2K | $0 |
| Financing cash flow | $1.8M | -$196.5K | $3.0M | $3.7M | -$5.4K | $2.4M | -$7.1K | -$3.8K |
| Free cash flow | -$1.9M | -$1.8M | — | — | -$1.7M | -$1.7M | -$2.0M | -$2.2M |
| Capital expenditures | $9.2K | $3.7K | — | — | $0 | -$2.2K | $2.2K | $0 |
| Depreciation & amortization | $72.9K | $79.5K | $81.6K | $79.9K | $82.6K | $83.9K | $83.8K | $85.8K |
| Share-based compensation | $50.0K | $206.1K | $72.4K | $72.4K | $72.4K | $275.9K | $90.0K | $113.5K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $4.5K | $975 | $1.2K | $3.3K | $5.4K | $2.9K | $7.1K | $3.8K |
Income statement
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $574.2K | $294.2K |
| Operating income | -$7.3M | -$9.3M | -$12.6M | -$11.9M | -$10.4M |
| Net income | -$7.2M | -$13.4M | -$12.2M | -$12.0M | -$10.4M |
| EPS (diluted) | $-10.61 | $-85.77 | $-38.87 | $-5.86 | $-0.71 |
| EPS (basic) | $-10.61 | $-85.77 | $-38.87 | $-5.86 | $-0.71 |
| Operating margin | — | — | — | -$2.1K | -$3.5K |
| Net margin | — | — | — | -$2.1K | -$3.5K |
Balance sheet
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Total assets | $6.3M | $7.4M | $8.2M | $17.5M | $19.4M |
| Total liabilities | $1.4M | $2.2M | $2.5M | $2.4M | $2.4M |
| Stockholders' equity | $4.9M | $5.1M | $5.8M | $15.1M | $17.0M |
| Total current assets | $5.6M | $5.9M | $6.2M | $15.1M | $18.2M |
| Total current liabilities | $1.4M | $1.9M | $1.8M | $1.5M | $1.8M |
| Cash & equivalents | $5.0M | $5.5M | $5.4M | $14.5M | $17.1M |
| Accounts receivable | — | — | — | $0 | $128.0K |
| Property, plant & equipment | $356.8K | $676.2K | $1.0M | $1.1M | $441.2K |
| Intangible assets | $0 | $550 | $1.1K | $1.6K | $2.2K |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $384.6K | $534.5K | $777.9K | $432.9K | $500.0K |
| Deferred revenue (current) | — | — | — | $0 | $344.5K |
| Other current liabilities | $657.3K | $472.2K | $215.0K | $588.6K | $696.9K |
| Common stock & paid-in capital | $1.6K | $259 | $329 | $2.3K | $15.4K |
| Retained earnings | -$175.1M | -$168.0M | -$154.6M | -$142.4M | -$130.3M |
| Accumulated other comprehensive income (loss) | -$32.7K | -$17.1K | -$6.9K | -$6.1K | $0 |
Cash flow
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$7.6M | -$10.1M | -$10.5M | -$9.8M |
| Investing cash flow | -$3.7K | $0 | -$250.9K | -$943.1K | -$349.2K |
| Financing cash flow | $6.5M | $7.7M | $1.3M | $8.9M | $17.4M |
| Free cash flow | -$7.0M | -$7.6M | -$10.4M | -$11.4M | -$10.1M |
| Capital expenditures | $3.7K | $0 | $250.9K | $943.1K | $349.2K |
| Depreciation & amortization | $323.7K | $339.6K | $359.1K | $240.9K | $123.7K |
| Share-based compensation | $278.5K | $415.2K | $1.2M | $1.1M | $750.6K |
| Change in accounts receivable | — | — | $0 | -$128.0K | -$21.1K |
| Tax withholding on stock comp | $10.9K | $18.9K | $34.8K | $12.5K | $88.1K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AEMD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-04-23 to 2026-10-08
Recent transactions
- Most recent: LAROSA STEVEN P (Chief Medical Officer) — Grant / award of 42,000 shares on 2026-10-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| LAROSA STEVEN P | Chief Medical Officer | Grant / award | 2026-10-08 | 42,000 |
| FRAKES JAMES B | CFO/CEO | Grant / award | 2026-10-08 | 42,000 |
| Shah Chetan | Director | Tax withholding | 2026-09-30 | 436 |
| Gikakis Nicolas | Director | Tax withholding | 2026-09-30 | 436 |
| BROENNIMAN EDWARD G | Director | Tax withholding | 2026-09-30 | 218 |
| Rossetti Angela | Director | Grant / award | 2026-04-17 | 21,815 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-08 | LAROSA STEVEN P | Chief Medical Officer | Grant / award | 42,000 | $0.00 |
| 2026-10-08 | FRAKES JAMES B | CFO/CEO | Grant / award | 42,000 | $0.00 |
| 2026-09-30 | Shah Chetan | Director | Tax withholding | 436 | $6.52 |
| 2026-09-30 | Gikakis Nicolas | Director | Tax withholding | 436 | $6.52 |
| 2026-09-30 | BROENNIMAN EDWARD G | Director | Tax withholding | 218 | $6.52 |
| 2026-06-30 | Shah Chetan | Director | Tax withholding | 2,182 | $0.82 |
| 2026-06-30 | Gikakis Nicolas | Director | Tax withholding | 2,182 | $0.82 |
| 2026-06-30 | BROENNIMAN EDWARD G | Director | Tax withholding | 1,091 | $0.82 |
| 2026-04-17 | Rossetti Angela | Director | Grant / award | 21,815 | $2.29 |
| 2026-04-17 | Shah Chetan | Director | Grant / award | 21,815 | $2.29 |
| 2026-04-17 | BROENNIMAN EDWARD G | Director | Grant / award | 21,815 | $2.29 |
| 2026-04-17 | Gikakis Nicolas | Director | Grant / award | 21,815 | $2.29 |
| 2026-03-31 | Shah Chetan | Director | Tax withholding | 178 | $2.19 |
| 2026-03-31 | Gikakis Nicolas | Director | Tax withholding | 178 | $2.19 |
| 2026-03-31 | BROENNIMAN EDWARD G | Director | Tax withholding | 89 | $2.19 |
| 2025-12-31 | Shah Chetan | Director | Tax withholding | 179 | $2.77 |
| 2025-12-31 | Gikakis Nicolas | Director | Tax withholding | 179 | $2.77 |
| 2025-12-31 | BROENNIMAN EDWARD G | Director | Tax withholding | 89 | $2.77 |
| 2025-09-30 | Shah Chetan | Director | Tax withholding | 1,786 | $0.75 |
| 2025-09-30 | Gikakis Nicolas | Director | Tax withholding | 1,786 | $0.75 |
| 2025-09-30 | BROENNIMAN EDWARD G | Director | Tax withholding | 893 | $0.75 |
| 2025-06-30 | BROENNIMAN EDWARD G | Director | Tax withholding | 893 | $1.20 |
| 2025-06-30 | Gikakis Nicolas | Director | Tax withholding | 1,786 | $1.20 |
| 2025-06-30 | Shah Chetan | Director | Tax withholding | 1,786 | $1.20 |
| 2025-04-23 | Gikakis Nicolas | Director | Grant / award | 142,857 | $0.35 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:13 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 4 | 2026-10-08 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-08 | View on SEC.gov → |
| 2026-10-09 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-10-01 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-17 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-08-31 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
Recent news
Headlines about AEMD (Aethlon Medical, Inc.). Links open the publisher — we don’t host full articles.
-
Trading the Move, Not the Narrative: (AEMD) Edition
Stock Traders Daily · 2026-10-19 -
Amundi Index MSCI Emerging Mark (AEMD.SG) Stock Forum & Discussion
Yahoo! Finance Canada · 2026-10-17 -
Form 4 Aethlon Medical Inc: Angela Rossetti (Director) For: 17 April
Investing.com Nigeria · 2026-10-15 -
Form 4 Aethlon Medical Inc: Nicolas Gikakis (Director) For: 30 September
Investing.com Nigeria · 2026-10-15 -
JANE STREET GROUP, LLC Expands Aethlon Medical Inc (AEMD) Stake with 28,043-Share Purchase
GuruFocus · 2026-10-15 -
Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha · 2026-10-01 -
Key deals this week: SPGI, PSO, GEHC, and more
Seeking Alpha · 2026-09-20 -
Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger
Yahoo Finance · 2026-09-17
No headlines in this category right now — try “All”.